title: ▾Glycopyrronium for COPD.
abstract: ▾Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).¹ This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▾Indacaterol for COPD² and ▾Aclidinium for COPD?³). The company's promotional material claims that 'Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD'.⁴ In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.
mesh_terms: D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D006024:Glycopyrrolate